evipedia.ai
← Back

Disodium Succinoyl Farnesylcysteine for Skin Rejuvenation

Evidence Review created on 10/04/2026 using AI4L / Opus 5.5

Also known as: SFC, N-Succinyl-S-farnesyl-L-cysteine, Succinoyl Farnesylcysteine

Motivation

Disodium succinoyl farnesylcysteine (SFC) is a laboratory-made skincare ingredient. It joins an amino acid to a fatty chain that cells naturally attach to some of the proteins that carry messages inside them. The compound was designed to quiet the inflammatory signals that sunlight, pollution and irritants set off in skin, a process thought to speed up visible skin aging.

The ingredient grew out of decades of university research into how these fat-tagged proteins pass messages through cells, and a small company later adapted the chemistry for cosmetics. Its developer has tested it in a handful of human studies, including one that set it beside a widely used vitamin-based skincare ingredient. Recently it has moved from a niche raw material to the headline active of several longevity-branded skincare lines, drawing attention from people seeking to keep their skin healthy as part of a broader longevity approach.

This review examines whether applying the compound to the skin changes wrinkles, hydration and redness, what is known about its safety, how it is used in practice, and how much of the available evidence is independent of the companies that own or sell it.

Benefits - Risks - Protocol - Conclusion

This section lists overview resources that discuss SFC or its isoprenylcysteine (cysteine carrying a fat-like chain) mechanism in depth.

Only two items qualify. Overview content on SFC is scarce: almost all published material comes from its developer (one item allowed per organization), from brands selling it, or from general commentary that mentions it only briefly. None of the priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension, Lifespan.io) has published content on SFC or isoprenylcysteines; both web and on-site searches returned no results.

Grokipedia

No Grokipedia article on disodium succinoyl farnesylcysteine exists; the only related entry describes a commercial moisturizer that contains it.

Examine

No Examine article on disodium succinoyl farnesylcysteine exists.

ConsumerLab

No ConsumerLab article on disodium succinoyl farnesylcysteine exists.

Systematic Reviews

No systematic reviews or meta-analyses for Disodium Succinoyl Farnesylcysteine were found on PubMed as of 2026-10-04.

Neither the claimed skin benefits nor the principal risk, skin irritation, is represented by any systematic review or meta-analysis.

Mechanism of Action

SFC is the disodium salt of N-succinyl-S-farnesyl-L-cysteine: cysteine carrying a 15-carbon farnesyl fat chain. It mimics the fat-tagged tail of G proteins (switch proteins that relay messages from cell-surface receptors); the parent compound AFC blocks a processing step of that tail and interferes with receptor signaling (Volker et al., 1991). Isoprenylcysteines are also proposed to compete with the tail for membrane docking sites, dampening signaling from G-protein-coupled receptors.

In the developer’s cell studies (Fernández et al., 2021), SFC:

  • Reduced IL-6 (interleukin-6, an inflammatory messenger) release triggered by LL-37 (cathelicidin, a skin antimicrobial peptide linked to rosacea, a chronic facial redness disorder) acting on FPRL1 (formyl peptide receptor-like 1, a receptor on immune and blood-vessel cells)
  • Reduced IL-8 (interleukin-8, a white-cell attractant) release triggered through TLR2 (toll-like receptor 2, a sensor for bacterial components)
  • Reduced MMP-1 (matrix metalloproteinase-1, a collagen-degrading enzyme) induced by UVA (long-wave ultraviolet light reaching the deeper skin layer), and IL-6 and TNF-α (tumor necrosis factor-alpha, an inflammatory messenger) induced by UVB (short-wave, sunburn-causing ultraviolet light)

A competing reading: effective concentrations differ over 10,000-fold between assays, hard to reconcile with one target, and the soap-like structure may cause nonspecific membrane effects. No independent laboratory has tested SFC.

Pharmacology: no human data exist on skin penetration, half-life, selectivity, distribution or metabolism. Free farnesylcysteine is broken down by prenylcysteine lyase (PCYOX1, an enzyme that cleaves the farnesyl chain from cysteine) (Beigneux et al., 2002); whether SFC’s succinyl cap blocks this is untested.

Historical Context & Evolution

Isoprenylcysteines began as research tools, not skincare. In 1991 Jeffry Stock’s group at Princeton University reported that farnesylcysteine analogs such as AFC (N-acetyl-S-farnesyl-L-cysteine) block a processing step of fat-tagged signaling proteins and interfere with receptor signaling (Volker et al., 1991). AFC was then shown to blunt receptor-triggered platelet activation (Huzoor-Akbar et al., 1993) and immune-cell responses, establishing the class as anti-inflammatory signaling modulators.

Stock co-founded Signum Biosciences, which turned the chemistry toward skin. Topical AFC reduced chemical and allergic ear inflammation in mice without effects beyond the treated site (Gordon et al., 2008), and a Weill Cornell group working with Signum scientists found that AFC suppresses inflammatory signals from skin blood-vessel cells (Adhami et al., 2012). Signum’s cosmetic arm, Signum Dermalogix, next developed analogs with a 20-carbon phytyl chain, one of which was sold in a night cream (Fernández et al., 2019).

SFC is covered by a Signum patent with a 2008 priority date (US10314802B2). Its first human tests were a 100-subject patch test and the 2021 split-face wrinkle trial, followed by a 2023 rosacea pilot. Interest rose in 2025, when Bryan Johnson’s Blueprint brand, which sells SFC products, made it the lead active of its skincare line (Blueprint). Formulators have questioned the claims, noting that the evidence comes from the ingredient’s owner (Lissa, 2025). No finding has been refuted; the record is simply thin and single-source.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the only controlled human data come from a single split-face trial run by the compound’s owner, with no replication by an independent research group.

Medium 🟩 🟩

Reduced Crow’s-Feet Wrinkles

In a 12-week double-blind split-face trial by Fernández and colleagues at Signum Biosciences, 31 Japanese women applied 1% SFC gel to one side of the face and vehicle (the same gel without the active) to the other, twice daily (Fernández et al., 2021). Crow’s-feet were graded on the JSCC scale (Japanese Society of Cosmetic Chemists 0–7 wrinkle grades). No between-group test against a separate 5% niacinamide group (18 women) is reported. Uncontrolled Signum studies of phytyl analogs reported fine-line gains (Fernández et al., 2016), indirect support only.

Magnitude: At week 8, wrinkle grade improved about 32% from baseline on the SFC side versus about 6% on the vehicle side, reported as statistically significant versus vehicle; no between-side difference or 95% CI (confidence interval, the range likely to hold the true effect) was reported.

Improved Skin Texture, Hydration and Radiance

In the same trial (Fernández et al., 2021), investigators graded texture, visible hydration, radiance and overall appearance on a modified Griffiths 0–9 scale. The text reports SFC outperforming vehicle for tactile texture and visible hydration at weeks 8 and 12, and radiance and visual texture at week 12, but the table tests each side only against its own baseline (a paired before-after test). Overall appearance showed no significant gain by week 12. A phytyl analog showed similar uncontrolled gains (Fernández et al., 2016), indirect support. Vehicle-treated skin improved too.

Magnitude: Share of participants improved at week 12, SFC side versus vehicle side: visible hydration 80.6% vs 59.2%, radiance 51.6% vs 24.5%, visual texture 38.7% vs 16.3%, overall appearance 22.6% vs 8.2% (neither significant versus baseline) (not compared between groups).

Low 🟩

Skin Firmness ⚠️ Conflicted

In the Fernández split-face trial (Fernández et al., 2021), tactile firmness improved on the SFC side but not significantly more than on the vehicle side. Uncontrolled studies of a different, phytyl-chain compound reported firmness gains (Fernández et al., 2016). Net reading: no firmness effect beyond vehicle has been shown.

Magnitude: Firmness improved 19% from baseline on the SFC side (p = 0.031; p value, the probability of a result this large arising by chance) versus about 10% on the vehicle side (p = 0.063); the difference from vehicle was not statistically significant.

Reduced Rosacea Redness and Bumps ⭕️ Not Central to Skin Rejuvenation

Rosacea is a chronic facial condition causing redness and acne-like bumps. In an open-label pilot (participants knew their treatment) by Pérez and colleagues at Signum Biosciences, 10 adults applied 3% SFC gel twice daily for 4 weeks (Pérez et al., 2023). This bears on skin disease, not aging.

Magnitude: Mean inflammatory lesion count fell by almost 50% from baseline and 7 of 10 participants had less redness after 4 weeks (no control group).

Speculative 🟨

Protection Against UV-Driven Collagen Breakdown

In fibroblast cultures (collagen-producing skin cells), SFC blocked UVA-induced release of the collagen-degrading enzyme MMP-1 (Fernández et al., 2021). No human study has measured this; the basis is laboratory data only.

Calming of Irritant and Allergic Skin Inflammation ⭕️ Not Central to Skin Rejuvenation

Topical AFC, SFC’s parent compound, reduced chemical and allergic ear inflammation in mice (Gordon et al., 2008). This bears on dermatitis (skin inflammation), not aging. No human data exist; the basis is animal work.

Benefit-Modifying Factors

  • Genetic variants: No genetic variant has been studied as a modifier of SFC response. Variants in TLR2, the bacterial-sensing receptor SFC inhibits in cells, influence inflammatory skin disease, but any effect on SFC’s benefit is unexplored.
  • Baseline wrinkle severity: The wrinkle trial (Fernández et al., 2021) enrolled only mild-to-moderate crow’s-feet (JSCC grade 3–5 of 7). Benefit for very fine lines or deep, fixed folds is unknown.
  • Baseline dryness: Large vehicle-side gains in visible hydration (Fernández et al., 2021) show that dry skin responds to any well-formulated gel, making SFC’s own contribution harder to detect in people starting with dry skin.
  • Sex: The wrinkle trial enrolled only women (Fernández et al., 2021); the rosacea pilot (Pérez et al., 2023) included three men among ten participants. No sex-specific analysis exists.
  • Pre-existing conditions: Inflammation-driven conditions such as rosacea are the clearest mechanistic target and the only disease studied. Benefit in eczema-prone or highly sensitive skin is untested.
  • Age and skin type: Ages in the wrinkle trial (Fernández et al., 2021) were not reported and all participants were Japanese women. Responses in other skin types, and at the older end of adulthood where skin is thinner and drier, are unknown.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no human study has documented harm from SFC, and the published tolerability statements come from one sponsor without adverse-event counts.

Medium 🟥 🟥

No risk reaches Medium: no controlled human study has reported adverse-event rates for SFC by treatment arm.

Low 🟥

Speculative 🟨

Contact Irritation or Allergy ⚠️ Conflicted

Topicals can irritate or sensitize skin (theoretical). The vehicle-controlled trial, an unpublished 100-subject patch test (Fernández et al., 2021) and a 10-patient pilot (Pérez et al., 2023) reported good tolerance. Net reading: no irritation documented.

Unknown Skin Penetration and Long-Term Safety

No data exist on how much SFC passes through skin, its metabolism, or use beyond 12 weeks. Its long-term safety rests on short sponsor studies; the basis for concern is mechanistic only.

Dampened Local Immune Defense

SFC inhibits TLR2 signaling in skin cells in culture (Fernández et al., 2021). Blunting this bacterial alarm could, in theory, weaken local responses to microbes; no such effect has been observed. Basis is mechanistic only.

Risk-Modifying Factors

  • Genetic variants: No genetic variant is known to change SFC tolerability; no pharmacogenetic data exist.
  • Baseline skin barrier: An impaired barrier, such as high TEWL (transepidermal water loss, water evaporating through skin), increases penetration and irritation of topicals generally; this is untested for SFC.
  • Sex: No sex difference in tolerability has been reported; sponsor safety data from about 140 users, with the 12-week trial enrolling only women, are too sparse to detect one.
  • Pre-existing skin disease: Active eczema, a history of allergic contact dermatitis, or broken skin raises irritation risk with any new topical; such people were not studied.
  • Pregnancy and breastfeeding: No absorption or exposure data exist; safety in pregnancy and breastfeeding is unknown.
  • Age: Thinner, drier skin at older ages may be more easily irritated; children have never been studied.

Key Interactions & Contraindications

  • Topical retinoids (vitamin A derivatives: tretinoin, tazarotene, adapalene): Caution (theoretical): additive dryness and redness possible. In a 5-person patch study by Signum and Rohto staff, a farnesyl analog did not reduce tretinoin irritation (Pérez et al., 2025). Mitigation: separate application times or alternate nights.
  • Topical corticosteroids (steroid anti-inflammatories: hydrocortisone, clobetasol) and calcineurin inhibitors (tacrolimus, pimecrolimus; non-steroid immune dampeners): Monitor (theoretical): overlapping anti-inflammatory action; no harm expected, but benefit attribution becomes unclear. Mitigation: application at separate times of day.
  • Prescription rosacea treatments (metronidazole, azelaic acid, ivermectin cream): Monitor (theoretical): possible additive reduction of redness, but stacking several actives raises cumulative irritation. Mitigation: introducing one new product at a time.
  • Oral prescription drugs (e.g., atorvastatin, warfarin): No interaction expected (theoretical); no clinical consequence anticipated, as skin absorption is unmeasured and presumed low. Statins (cholesterol-lowering drugs) reduce the body’s own farnesyl production, with no known bearing on topical SFC.
  • Exfoliating acids (glycolic acid, salicylic acid) and benzoyl peroxide (over the counter): Caution (theoretical): more stinging and redness; benzoyl peroxide, an oxidizer, may also degrade SFC’s sulfur bond. Mitigation: application at different times of day.
  • Over-the-counter sunscreens (zinc oxide, avobenzone) and moisturizers: Compatible (theoretical): no clinical consequence expected. SFC itself gives no UV protection, so it cannot substitute for sunscreen.
  • Topical niacinamide and other anti-inflammatory cosmetic actives (azelaic acid, centella extract): Compatible (theoretical): possible additive reduction of redness and dryness; no harm expected. The only trial tested niacinamide and SFC separately, never together.
  • Oral skin supplements (Polypodium leucotomos extract, astaxanthin, collagen peptides): Compatible (theoretical): possible additive dampening of UV-related skin inflammation with the first two; no harm expected. No study has combined them with SFC.
  • Skin procedures (laser resurfacing, chemical peels, microneedling): Avoid (theoretical) on freshly treated skin: deeper penetration and irritation are possible. Mitigation: resuming only after the skin surface has healed.
  • LED light therapy (light-emitting diode panels): Compatible (theoretical): no clinical consequence expected. LightStim sells an SFC serum for use with its devices; the combination is untested.

Populations who should avoid Disodium Succinoyl Farnesylcysteine:

  • People with known allergy to SFC or to any ingredient in the product
  • Skin with open wounds, active dermatitis or a recent resurfacing procedure at the application site (theoretical)
  • Pregnant or breastfeeding people, given no exposure data (theoretical)
  • Children, who have never been studied (theoretical)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Patch test before facial use: Applying the product to a small area of the inner forearm once daily for 3–5 days screens for contact irritation or allergy before full-face use.
  • Gradual introduction: Starting once daily for the first week, then moving to the twice-daily schedule used in trials, limits cumulative irritation, especially alongside retinoids or acids.
  • Separation from irritating actives: Applying SFC and retinoids, exfoliating acids or benzoyl peroxide at different times of day reduces additive stinging, dryness and redness.
  • Intact skin only: Avoiding broken, infected or freshly resurfaced skin limits unmeasured absorption and any theoretical weakening of local defense against microbes.
  • Eye-area care: Keeping product off eyelid margins and out of the eyes prevents eye irritation; the wrinkle trial applied it to the crow’s-feet area, not the eyelids.
  • Stopping rule: Stopping if redness, itching or swelling lasts beyond 48 hours, or if blistering appears, limits progression of contact dermatitis; no source gives a measured threshold.
  • Time-limited trial: Standardized photographs at baseline and 12 weeks limit open-ended use of an ingredient with no safety data beyond 12 weeks and uncertain benefit.

Therapeutic Protocol

Each dose below is cited to its source; other parameters without a citation (timing, titration, duration) reflect common practice.

  • Wrinkle and appearance regimen: 1% SFC gel applied twice daily to the face for 12 weeks, the trial regimen of Signum Biosciences (Fernández et al., 2021).
  • Rosacea regimen: 3% SFC gel applied twice daily for 4 weeks, the pilot regimen of Signum Biosciences (Pérez et al., 2023).
  • Blueprint layered regimen: Bryan Johnson’s Blueprint brand popularized a cleanser, serum and moisturizer each containing SFC, used morning and evening (Blueprint); concentrations are undisclosed and the regimen is untested.
  • LED-paired regimen: LightStim pairs its SFC serum with LED sessions (LightStim); the concentration is undisclosed and the pairing is untested.
  • Established alternatives: Topical options with larger evidence bases include niacinamide (e.g., a Procter & Gamble split-face trial, Bissett et al., 2005) and tretinoin; SFC is used either instead of or layered with them.
  • Time of day: Morning and evening, as in both trials; morning use sits under sunscreen, and evening use can be separated from retinoids.
  • Half-life: No human pharmacokinetic data exist; skin residence time and half-life are unknown. Twice-daily use follows trial design, not measured kinetics.
  • Single or split doses: Split into two daily applications in both trials; no once-daily regimen has been tested.
  • Genetic factors: No pharmacogenetic variant (e.g., in skin-enzyme genes) is known to affect SFC; no dose adjustment by genotype exists.
  • Sex: Wrinkle data come from women only; no sex-specific dosing has been studied.
  • Age: Trial ages were not reported and no age-specific dosing exists; older, thinner skin may tolerate a once-daily start better.
  • Baseline status: Benefit was shown in mild-to-moderate crow’s-feet (JSCC 3–5); baseline wrinkle, dryness and redness grades set the reference for judging response.
  • Pre-existing conditions: Rosacea used the higher 3% gel; eczema-prone or sensitive skin is untested, and a slower, once-daily start is common practice there.

Discontinuation & Cycling

  • Intended duration: Used as an ongoing cosmetic rather than a short course; no study has followed users beyond 12 weeks.
  • After stopping: No study has measured what happens after stopping; whether wrinkle or hydration changes persist or fade is unknown.
  • Withdrawal effects: None known; no rebound redness or dryness has been reported.
  • Tapering: Not required; no taper protocol exists and nothing suggests one is needed.
  • Cycling: No evidence that cycling maintains efficacy and no data on tolerance developing with continuous use.

Sourcing and Quality

  • Single proprietary source: SFC is patented (US10314802B2), with rights now held by Signum Dermalogix; retail products depend on the patent holder’s supply.
  • Ingredient-list check: Genuine products list “Disodium Succinoyl Farnesylcysteine” by its INCI name (International Nomenclature of Cosmetic Ingredients, the standard label name); “SFC” in marketing without that name cannot be verified.
  • Undisclosed concentration: Brands rarely state the SFC percentage, while the evidence used 1% and 3% gels. Ingredient-list position gives only a rough guide, since ingredients below 1% may appear in any order.
  • Third-party testing: Blueprint states its products are third-party tested, but no published assay confirms SFC content in any finished product.
  • Formulation and packaging: The trials used a gel. Opaque, airless packaging limits oxidation of the unsaturated farnesyl chain (common practice).
  • Products on the market: Blueprint SFC Facial Serum, Moisturizer and Gentle Facial Cleanser (with NMN, nicotinamide mononucleotide, a vitamin B3 derivative); LightStim PhotoSerum. Claims such as “5x more powerful than niacinamide” lack between-group statistical support.

Practical Considerations

  • Time to effect: Visible hydration improved within 15 minutes of application on both SFC and vehicle sides; wrinkle changes appeared by week 8 (Fernández et al., 2021).
  • Common pitfalls: Assuming a retail product matches the 1% trial gel; reading “outperforms niacinamide” as proof from a head-to-head test; replacing sunscreen or better-studied actives with SFC.
  • Regulatory status: A cosmetic ingredient, not an approved drug. US cosmetics need no FDA (U.S. Food and Drug Administration) premarket approval (FDA); the EU (European Union) CosIng database (the Commission’s cosmetic ingredient register) lists it with the function “skin protecting” (CosIng).
  • Cost and access: Sold online in branded serums and creams; the Blueprint serum costs about €65–68 per month (Blueprint). Not exceptionally expensive, but costs add up across layered products.
  • Payer and funding incentives: Insurers and national health systems do not pay for cosmetic skin-aging products, so no payer bias for or against SFC is apparent; all research funding has come from the ingredient’s owner.

Interaction with Foundational Habits

  • Sleep: None (no direct interaction). SFC is topical and non-stimulating, so evening application fits pre-sleep routines. Short sleep independently worsens skin hydration and appearance, which could mask or mimic changes attributed to SFC.
  • Nutrition: None (no direct interaction). Diet does not alter a topical’s action, and SFC depletes no nutrients. Diets low in ultra-processed foods support skin health independently; no study has paired diet with SFC.
  • Exercise: Indirect. Heavy sweating can dilute or rinse off topicals, so application after post-exercise cleansing preserves contact time. Heat-triggered flushing in rosacea is the redness SFC was piloted against; no study tested SFC around workouts.
  • Stress management: Indirect, untested. Psychological stress worsens skin barrier function and triggers rosacea flares through inflammatory pathways overlapping those SFC dampens in cells; whether SFC offsets stress-related flares has not been studied.

Monitoring Protocol & Defining Success

Baseline testing before starting consists of standardized facial photographs under fixed lighting, plus a self- or clinician-graded record of crow’s-feet wrinkles, dryness and redness. No blood tests are needed, since SFC is applied to the skin and systemic effects have not been described. A 3–5 day forearm patch test serves as the baseline safety check.

Ongoing monitoring follows a simple cadence: skin checks at 1 week for irritation, then repeat photographs and grading at 8 and 12 weeks, the trial’s own timepoints, and every 6 months thereafter if use continues. Success is defined as visible improvement in wrinkle, hydration or redness grades versus baseline photographs at 12 weeks without irritation; lack of visible change indicates no response.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Crow’s-feet wrinkle grade No established target; track change from own baseline Expected to change JSCC 0–7 scale (Japanese Society of Cosmetic Chemists wrinkle grading); trial enrolled grades 3–5. Identical lighting, pose and expression keep images comparable; morning images can show pillow creases.
Skin hydration No established target; track change from own baseline Expected to change Visual grading or a corneometer (a probe measuring surface water, in arbitrary units). Readings taken at least 12 hours after the last application and after 20 minutes of room acclimatization avoid the brief rise products cause.
Facial redness grade No established target; track change from own baseline Expected to change (rosacea); safety check (new redness) Rising redness after starting signals irritation rather than benefit. Best paired with lesion counts in rosacea; grading after exercise, heat or alcohol is unreliable.
Local irritation score No established target; track new symptoms from own baseline Safety check: persistent stinging, scaling or swelling stops use Record at 1 week and after adding any new active (e.g., a retinoid).

Qualitative markers:

  • Skin comfort and absence of stinging or tightness
  • Perceived smoothness and softness to touch
  • Visible glow or evenness in natural light
  • Frequency and duration of redness flares

Emerging Research

  • No registered trials: A ClinicalTrials.gov search on 2026-10-04 for SFC, farnesylcysteine, isoprenylcysteine and Signum found no registered trial (no NCT ID, the registry number, exists), so no ongoing study is expected to change the evidence soon.
  • Independent replication: The wrinkle and appearance findings rest on one sponsor-run trial (Fernández et al., 2021). An independent vehicle-controlled trial reporting between-side statistics could raise wrinkle evidence toward High, or erase the effect.
  • Controlled rosacea trial: The rosacea pilot was open-label with 10 people (Pérez et al., 2023); a vehicle-controlled trial would show whether redness and bump reductions exceed placebo-like improvement.
  • Farnesyl versus phytyl chains: A 2025 Signum pilot found a phytyl analog reduced tretinoin irritation while a farnesyl analog had little effect (Pérez et al., 2025), a signal that could weaken expectations for farnesyl compounds such as SFC as retinoid companions.
  • Skin penetration and metabolism: No study has measured SFC’s absorption, skin levels or breakdown. Such data would show whether cell-culture concentrations are reached in living skin, strengthening or undermining the mechanism.
  • Analog class results: Phytyl-chain relatives improved acne and aging signs in sponsor trials (Fernández et al., 2012; Fernández et al., 2019); independent tests of the class would clarify whether these signals extend to SFC.
  • Long-term and real-world safety: Use beyond 12 weeks and in layered retail regimens is unstudied; post-marketing reports of irritation or allergy, if they appear, could change the safety picture.

Conclusion

Disodium succinoyl farnesylcysteine is a laboratory-made cosmetic ingredient designed to quiet inflammatory signals in skin. For health-focused adults looking for skin-applied tools against visible aging, it is a new option with a thin, single-source evidence base.

The most direct evidence comes from one controlled study in women, in which skin treated with the ingredient showed fewer crow’s-feet wrinkles than skin treated with the same gel without it; hydration, texture and radiance also improved, but the plain gel improved them too, so the ingredient’s own share is unclear. Skin firmness did not improve beyond the plain gel, and comparisons with the vitamin-based ingredient it is marketed against were never properly tested. A small study without a comparison group suggests it may calm the redness and bumps of a common facial redness condition. Its claimed protection of collagen against sunlight rests only on laboratory work.

No harm has been documented, but safety information is limited to a few short studies by the developer, with nothing known about long-term use or how much of the compound passes through the skin.

The weight of the evidence is shaped by who produced it. Every human study was run and authored by the company that owns the ingredient, whose staff hold shares in it, and the most visible brand selling it profits directly from its use. No independent group has tested it in people. The benefits look plausible but modest and unconfirmed, and the ingredient sits alongside better-studied skin-applied options rather than above them.

Top - Benefits - Risks - Protocol